Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lifeward Ltd.LFWD · Entity 7620 | Director | March 25, 2026 | March 27, 2026 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Director | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lifeward Ltd.
Report date March 25, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, no par value per shareSEC Table I · non-derivative | Direct | 7,657 |
Reported balance
After 2026-03-25 transaction · row 1
1 source rowRow 1 · 2026-03-25 · Grant · Acquired 7,657 · Balance 7,657 F1: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date.
ORAMED PHARMACEUTICALS INC.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,180 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Grant · Acquired 30,000 · Balance 98,930 F1: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. Row 2 · 2025-12-31 · Grant · Acquired 6,250 · Balance 105,180 F2: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.
F2: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2026 Filed Mar 27, 2026 16:56 UTC | Lifeward Ltd. LFWD · Entity 7620 | GrantOrdinary Shares, no par value per share | 7,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-001816 · ownership.xml · nonDerivative · entry 1 Reznick Yehuda · CIK 0002015556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,657 F1 · shares: Represents 7,657 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on March 25, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months from the Grant Date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:21 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-001282 · ownership.xml · nonDerivative · entry 2 Reznick Yehuda · CIK 0002015556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,180 F2 · shares: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. F2 · price: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:21 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-001282 · ownership.xml · nonDerivative · entry 1 Reznick Yehuda · CIK 0002015556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,930 F1 · shares: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:08 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 8,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-052622 · ownership.xml · nonDerivative · entry 2 Reznick Yehuda · CIK 0002015556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,930 F2 · price: Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:08 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-052622 · ownership.xml · nonDerivative · entry 1 Reznick Yehuda · CIK 0002015556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,560 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 760 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-051336 · ownership.xml · nonDerivative · entry 1 Reznick Yehuda · CIK 0002015556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,560 F1 · price: Represents a grant of 760 Restricted Stock Units ("RSUs") that will vest in two equal installments on October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 00:07 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 29,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-034222 · ownership.xml · nonDerivative · entry 1 Reznick Yehuda · CIK 0002015556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,800 F1 · price: Represents (i) a grant of 22,500 Restricted Stock Units ("RSUs") that will vest in equal installments on January 1, 2025, January 1, 2026 and January 1, 2027 and (ii) grants of 5,070 and 2,230 RSUs that will each vest in nearly equal installments on July 1, 2024, October 1, 2024 and January 1, 2025. In each case, the RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.